Patents by Inventor Meiling Li

Meiling Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11952582
    Abstract: Provided are a mutant HPPD polypeptide having high resistance to a herbicide and an encoding gene thereof, and an application thereof in an improved plant. The amino acid at position 282 of the mutant HPPD polypeptide is mutated from arginine to serine at a wild-type HPPD polypeptide. In addition, the mutant HPPD polypeptide further comprises an amino acid at position 349 that is mutated from glutamic acid to lysine, and/or an amino acid at position 156 that is mutated from alanine to valine. The mutated HPPD polypeptide can be used for cultivating plants having resistance to a herbicide having HPPD inhibition.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: April 9, 2024
    Assignee: CAS CENTER FOR EXCELLENCE IN MOLECULAR PLANT SCIENCES
    Inventors: Jiankang Zhu, Vipasha Verma, Feng Li, Meiling Zhang, Ming Li, Mei Chen
  • Patent number: 11935211
    Abstract: Systems and methods for image processing are provided in the present disclosure. The systems and methods may obtain an image; determine a current resolution level of the image; determine, based on the current resolution level of the image, from a group of resolution level ranges, a reference resolution level range corresponding to the image; determine a target processing model corresponding to the reference resolution level range; and/or determine a processed image with a target resolution level by processing the image using the target processing model, the target resolution level of the processed image being higher than the current resolution level of the image.
    Type: Grant
    Filed: August 23, 2021
    Date of Patent: March 19, 2024
    Assignee: SHANGHAI UNITED IMAGING HEALTHCARE CO., LTD.
    Inventors: Guobin Li, Renkuan Zhai, Meiling Ji
  • Patent number: 11597926
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 7, 2023
    Assignee: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Joerg Duschmalé, Martina Brigitte Duschmalé, Henrik Frydenlund Hansen, Troels Koch, Meiling Li, Adrian Schaeublin, Xi Shu, Yong Wu
  • Publication number: 20230002762
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicement.
    Type: Application
    Filed: April 14, 2022
    Publication date: January 5, 2023
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad Bleicher, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • Publication number: 20220033818
    Abstract: The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple independent mRNAs in TDP-43 depleted cells.
    Type: Application
    Filed: July 23, 2021
    Publication date: February 3, 2022
    Inventors: Congwei WANG, Christian WEILE, Martin EBELING, Lars JOENSON, Jonas VIKESAA, Ravi JAGASIA, Meiling LI
  • Publication number: 20210292358
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioa to internucleoside linkage of formula (I), wherein (A1), (A2) and R are as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: July 30, 2019
    Publication date: September 23, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad Bleicher, Troels KOCH, Adrian SCHAEUBLIN, Joerg Jakob Andreas DUSCHMALE, Martina Brigitte DUSCHMALE, Meiling LI, Erich KOLLER
  • Publication number: 20210221837
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorotrithioate internucleoside linkage of formula (I) as defined herein. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: July 29, 2019
    Publication date: July 22, 2021
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Joerg Jakob Andreas DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Troels KOCH, Erich KOLLER, Meiling LI, Adrian SCHAEUBLIN
  • Publication number: 20210115438
    Abstract: The present invention relates to a compound of formula (II) or (IIb) Wherein X, Y, Rx, Ry, R5 and Nu are as defined in the description and in the claims. The compound of formula (II) can be used in the manufacture of oligonucleotides.
    Type: Application
    Filed: December 21, 2018
    Publication date: April 22, 2021
    Applicant: ROCHE INNOVATION CENTER COPENHAGEN A/S
    Inventors: Konrad BLEICHER, Joerg DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Henrik Frydenlund HANSEN, Troels KOCH, Meiling LI, Adrian SCHAEUBLIN, Xi SHU, Yong WU
  • Patent number: 10927023
    Abstract: A method may add whey to high calcium papermaking industrial wastewater blended and pre-acidification treatment to promote anaerobic reaction and inhibit calcification. The method includes, before anaerobic treatment of papermaking wastewater, mixing whey wastewater with the papermaking wastewater. The method also includes pre-treating the papermaking wastewater by acidification to stabilize the papermaking wastewater prior to entering an anaerobic reaction system.
    Type: Grant
    Filed: July 23, 2020
    Date of Patent: February 23, 2021
    Inventors: Shuangfei Wang, Zhiwei Wang, Hui Liu, Chengrong Qin, Chen Liang, Xueping Song, Lianxin Luo, Xinliang Liu, Meiling Li
  • Publication number: 20210032139
    Abstract: To promote anaerobic digestion and delay calcification, one or more signal molecules are used to regulate the microenvironment of anaerobic granular sludge. In the process of anaerobic granular sludge treatment of papermaking wastewater, AHLs (N-acyl Hyperserine Lactones) are added to papermaking wastewater before the papermaking wastewater enters the anaerobic reactor. This may occur when the proportion of microorganism in anaerobic granular sludge VSS/TSS is less than 0.6. Further, the addition of the one or more signal molecules changes the community structure of the bacteria and methanogens, promoting anaerobic digestion and delay calcification. Additionally, the microenvironment of granular sludge is regulated by adding one or more micro-signal molecules to improve the number of bacteria susceptible to calcification, improve the anaerobic digestion rate of sludge that has not been calcified, and delay the calcification rate.
    Type: Application
    Filed: June 30, 2020
    Publication date: February 4, 2021
    Inventors: Shuangfei Wang, Zhiwei Wang, Meiling Li, Shuangquan Yao, Jian Zhang, Jinghong Zhou, Peng Lu, HongXiang Zhu, Shuangxi Nie
  • Publication number: 20210032138
    Abstract: A method may add whey to high calcium papermaking industrial wastewater blended and pre-acidification treatment to promote anaerobic reaction and inhibit calcification. The method includes, before anaerobic treatment of papermaking wastewater, mixing whey wastewater with the papermaking wastewater. The method also includes pre-treating the papermaking wastewater by acidification to stabilize the papermaking wastewater prior to entering an anaerobic reaction system.
    Type: Application
    Filed: July 23, 2020
    Publication date: February 4, 2021
    Inventors: Shuangfei WANG, Zhiwei WANG, Hui LIU, Chengrong QIN, Chen LIANG, Xueping SONG, Lianxin LUO, Xinliang LIU, Meiling LI
  • Patent number: 10882884
    Abstract: The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates to a method for synthesizing stereodefined phosphorothioate MOE oligonucleotides using said novel chiral phosphoramidites.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: January 5, 2021
    Assignee: ETH ZURICH
    Inventors: Jonathan Hall, Meiling Li
  • Publication number: 20200339982
    Abstract: The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 29, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Henrik Frydenlund HANSEN, Troels KOCH, Jesper WORM, Adrian SCHAEUBLIN, Erik FUNDER, Joerg DUSCHMALÉ, Lars JOENSON, Meiling LI, Martina Brigitte DUSCHMALÉ, Yong WU, Xi SHU
  • Publication number: 20200332289
    Abstract: The present invention relates to a gapmer oligonucleotide comprising at phosphorodithioate internucleoside linkage of formula (I) as defined in the description and in the claims. The oligonucleotide of the invention can be used as a medicament.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 22, 2020
    Applicant: Roche Innovation Center Copenhagen A/S
    Inventors: Konrad BLEICHER, Joerg DUSCHMALÉ, Martina Brigitte DUSCHMALÉ, Henrik Frydenlund HANSEN, Erik FUNDER, Troels KOCH, Meiling LI, Adrian SCHAEUBLIN, Xi SHU, Yong WU
  • Publication number: 20190135849
    Abstract: The present invention relates to chiral phosphoramidites represented by formula (Ia) or formula (Ib) as novel monomers for the synthesis of stereodefined phosphorothioate MOE oligonucleotides. Furthermore, the present invention relates to a method for synthesizing stereodefined phosphorothioate MOE oligonucleotides using said novel chiral phosphoramidites.
    Type: Application
    Filed: May 18, 2017
    Publication date: May 9, 2019
    Inventors: Jonathan HALL, Meiling LI
  • Publication number: 20050239286
    Abstract: A two-step stripping method for removing via photoresist during the fabrication of trench-first partial-via dual damascene features is disclosed. In the first cleaning step, inert gas (He, Ar, N2)/fluorocarbon plasma is used to contact the remaining “Via Photo” for a short time period not exceeding 20 seconds. Thereafter, in the second cleaning step, a reducing plasma is used to completely strip the remaining “Via Photo”, thereby preventing the low-k or ultra low-k carbon-containing dielectric layer from potential carbon depletion.
    Type: Application
    Filed: October 27, 2004
    Publication date: October 27, 2005
    Inventors: Chih-Ning Wu, Wen-Liang Lien, Charlie Lee, Meiling Li